Trial Profile
A phase 2 interventional single arm study describing platelet responses and ITP remission rates in adult subjects with immune thrombocytopenia purpura receiving romiplostim
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Dec 2021
Price :
$35
*
At a glance
- Drugs Romiplostim (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Therapeutic Use
- Sponsors Amgen
- 14 Dec 2021 Results of subgroup analysis presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 01 Jun 2020 Results of integrated analysis of five clinical trials evaluating the efficacy and safety of romiplostim self-administration published in the American Journal of Hematology
- 18 Oct 2019 According to an Amgen media release, based on the results of this trial, the U.S. FDA has approved romiplostim for an additional indication of treatment of newly diagnosed and persistent adult Idiopathic-thrombocytopenic-purpura patients who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.